GlassScriptPhysician profile
Nathania Consolini
NPI 1457100083
$5,569.75
in general payments reported to CMS, 2019-2025
21 companies · $5,287 in 2025
The $5,287 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $283 · 2025: $5,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,470 · Education: $99.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,470.49 |
| Education | $99.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $904.34 | 2024-2025 | |
| Ucb, INC. | $625.37 | 2025 | Bimzelx |
| Janssen Biotech, INC. | $479.65 | 2025 | Tremfya |
| Incyte Corporation | $444.98 | 2025 | Opzelura, Opzelura |
| Leo Pharma INC. | $441.62 | 2025 | Adbry, Anzupgo |
| Genzyme Corporation | $407.41 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $339.92 | 2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $333.56 | 2025 | Taltz, Ebglyss, Zepbound |
| Amgen INC. | $274.73 | 2025 | Otezla |
| Sun Pharmaceutical Industries INC. | $268.22 | 2025 | |
| Galderma Laboratories, L.P. | $260.94 | 2024-2025 | Nemluvio, Dysport |
| Revance Therapeutics, INC. | $239.15 | 2024-2025 | Daxxify |
| Pfizer INC. | $212.59 | 2025 | |
| Organon LLC | $97.86 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $69.93 | 2024 | Tremfya |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $60.09 | 2025 | Ayvakit |
| Arcutis Biotherapeutics, INC. | $37.14 | 2025 | Zoryve |
| Almirall LLC | $26.76 | 2025 | Seysara, Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.83 | 2025 | Cabtreo |
| Novartis Pharmaceuticals Corporation | $14.07 | 2025 | |
| Mayne Pharma Commercial LLC | $12.59 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathania Consolini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.